


<b>Name</b>	<b>Sabah Akrawi</b>			
<b>Specialization</b>	Clinical Pharmacokinetics & Biopharmaceutics			
<b>Current Position</b>	Associate Professor			
<b>Contact email (Official)</b>	sakrawi@kfu.edu.sa	<b>Mobile :</b>	0504922094	
<b>Alternate email</b>	Shakrawi51@yahoo.com	<b>IP Phone :</b>	6989	
<b>Academic Qualifications</b>	<b>Degree/year/university/country</b>	PhD. 1988 College of Pharmacy / Univ. of Kentucky/ USA		
	<b>Degree/year/university/country</b>	BSc. Pharmacy College of Pharmacy / Univ. of Baghdad/ Iraq		
<b>Teaching Experience</b>	2012 to date Assoc. Prof. College of Clinical Pharmacy / King Faisal University. 2007 – 2009 Assoc. Prof. College of Pharmacy / Applied Sciences University. 1996 – 2000 Assoc. Prof. College of Pharmacy / Baghdad University. 1989 – 1996 Assis. Prof. College of Pharmacy / Baghdad University.			
<b>All the Courses Taught and Teaching in KFU with Course number</b>	<ul style="list-style-type: none"> <li>➤ - Clinical Pharmacokinetics</li> <li>➤ - Pharmaceutical Care I</li> <li>➤ - Pharmaceutical Care II</li> <li>➤ - Pharmaceutical Care III</li> <li>➤ Self-care and nonprescription drugs</li> </ul>			
<b>Research Interests</b>	<ul style="list-style-type: none"> <li>➤ Bioavailability studies (Clinical &amp; Analytical studies)</li> <li>➤ Bioequivalence studies (Clinical &amp; Analytical studies)</li> <li>➤ Drug – Drug interactions (Clinical studies)</li> <li>➤ Drug – Food interactions (Clinical studies)</li> <li>➤ Drugs Pharmacokinetics studies</li> <li>➤ Biopharmaceutics studies</li> <li>➤ Relationship between Pharmacokinetics parameters and Therapeutic effects</li> </ul>			
<b>Research Grants Received</b>	1. Determination of the active ingredients of Prosobis Farcta leaves, DSR grant.			

1. "Mephenytoin stereoselective elimination in the rats: II-Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration". Sabah H. Akrawi and Peter J. Wedlund, *European J. of drug metabolism and pharmacokinetics*; Vol. 14, No. 4, pp. 269-278; 1989.
2. "Mephenytoin stereoselective elimination in the rats: III. Stereoselective time course of induction during chronic hepatic portal vein administration". Sabah H. Akrawi and Peter J. Wedlund, *European J. of drug metabolism and pharmacokinetics*; *European J. of drug metabolism and pharmacokinetics*; 1989.
3. "Tissue distribution of INDIUM-III labeled poly (Glycolic Acid) matrices following jugular and hepatic portal vein administration". A.M. Hazrati, S. Akrawi, A.J. Hicky, P. Wedlund, J. Macdonald and P.P. Deluca, *J. of Controlled Release*, 9, pp. 205-214, 1989.
4. "The effect of alphotocopherol on experimentally induced gentamicin nephrotoxicity in rats". Abdulla T.M. Al-Ani, Marwan S.M. Al-Nimer and Sabah H. Akrawi, *Iraqi J. Pharm. Sci.* Vol 5(1) 1994.
5. "Nosocomial infections in three of Erbil's Hospitals". Kawa F. Dizayee and Sabah H. Akrawi. *Iraqi J. Pharm. Sci.* Vol. 6(1) 1995.
6. "Effect of molsidomine on trace metals in gentamicin induced nephrotoxicity in rats". Sabah H. Akrawi, Faris S. Allah-Werdi and Marwan S.M. Al-Nimer, *Iraqi J. Pharm. Sci.* Vol. 6(1) 1995.
7. "Prescribing errors in selected Hospital and Private Clinics in Baghdad". Sabah H. Akrawi. *Iraqi J. Pharm. Sci.* Vol. 7 1996.
8. "The evaluation of renoprotective effect of L-carnitine against gentamicin nephrotoxicity". Sabah H. Akrawi. *Iraqi J. Pharm. Sci.* Vol. 7 1996.
9. "Changes in brain glucose and glycogen in epileptic mice", S.P. Jazrawi and S.H. Akrawi, *Al-Buhooth Al Tachaniya*, Vol 9 ,N0 33, 1996.
10. "Effect of L-carnitine on lipid peroxidation in gentamicin induced nephrotoxicity in rats". Marwan S.M. Al-Nimer, Sabah H. Akrawi, Suhad Kh, Al-Jubory. *Iraqi J. Pharm. Sci.* Vol. 8(1) 1997.
11. "Potentiation of Gentamicin Induced Nephrotoxicity by Molsidomine in Rats". Sabah H. Akrawi and Marwan S.M. Al-Nimer, *Iraqi J. Pharm. Sci.* Vol. (9) 1998.
12. "Bioavailability – Bioequivalency study of a formulation containing Cephalexin", Sabah H. Akrawi, *The Iraqi Journal of Community Medicine*, 2000.
13. "Bioequivalence Assessment of Doloraz® 100 mg Suspensions in Healthy Human Volunteers". Sabah H. Akrawi, Ziad Al-Talla', Sabah D. Salim and Loay Rashan. *Iraqi Journal of Pharmacy*, Vol 3. No. 1, 2003.
14. "Bioequivalence study of indomethacin test product (25 mg capsule)" Haidar F. Hadi. Sabah H. Akrawi and Salim A. Hamadi, *Iraqi J. Pharm Sci*, vol 13. 2002.
15. "Bioequivalence Assessment of Clindox® 150 mg Capsules in Healthy Human Volunteers". Sabah H. Akrawi, Ziad Al-Talla', Sabah D. Salim and Loay Rashan. *Iraqi Journal of Pharmacy*, Vol 3. No. 1, 2003.
16. 'Bioequivalence Assessment of Hypoten® 100 mg Tablets in Healthy Human Volunteers and Treatment Monitoring'. Sabah H. Akrawi, *Iraqi Journal of Pharmacy*, Vol 3. No. 1, 2003.
17. "A two way cross over bioequivalence study for two formulations (100 mg suppository) containing indomethacin and treatment monitoring" Sabah H. Akrawi and Haidar F. Hadi. *J. Appl. Sci.*, Vol. 7, No. 1, 38-47, 2005
18. "Solid State NMR and Bioequivalence Comparison of the Pharmacokinetic Parameters of Two Formulations of Clindamycin" Zeyad A. Al-Talla1, Sabah H. Akrawi and Abdul-Hamid Emwas , *J. Clinical Therapeutics*, Vol. 49-No. 7/2011.
19. Bioequivalence assessment of two formulations of ibuprofen, Zeyad A. Al-Talla1, Sabah H. Akrawi, Luke T. Tolley, Salim H. Sioud, and Abdul-Hamid Emwas, *J. Drug Design, Development and Therapy*, 2011:5 427-433.

- 
20. "Pharmacokinetic Interaction between Dietary Black Tea and Carbamazepine in Epileptic Patients" Sabah H. Akrawi, Muna J. Hadi, Yasir Ibrahim, and Sabah Al-Dabbagh; Latin American Journal of Pharmacy; 34 (4), pp 754-9, **2015**.
  21. "The Evaluation of Reno-Protective Effect of L-Carnitine Against Gentamicin Nephrotoxicity" **Sabah H. Akrawi** and Suhad Kh. Al-Juboury; Latin American Journal of Pharmacy; 36 (8), pp 1586-8, **2017**.
  22. Determination of the active ingredients of the Propolis Farcta leaves extract; **Sabah Akrawi**; Mahesh Attimarad; and Bander AlDhubaib; **2019** Inpress.
- 
1. "Two-Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing rifampicin", Alaa Abbas & Sabah Akrawi, Thesis, 2001.
  2. "Effect of hepatic blood flow on diurnal variation of CBZ steady state level during chronic portal vein infusion in rats". Abdula Al Dhaw, Sabah Akrawi and P.J. Wedlund, 2000.
  3. "Lisinopril versus Captopril in hypertensive patients with and without renal impairment". Delshad Nori, Ali Farag Al-Saleh and Sabah Akrawi , 2000.
  4. "The effect of prednisolone and antibiotic treatment on sperm function test and sperm agglutination in infertile men", Hiwa K. Saeed, M.T. Albarzanchi and Sabah Akrawi, Thesis, 1999.
  5. "Determination of nifedipine concentration in human serum", Sahar M. Ali and Sabah Akrawi, Thesis, 1999.
  6. "Two-Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide and Treatment Monitoring", Niazy B. Al-Deen and Sabah Akrawi, Thesis, 1999.
  7. "The bioavailability-bioequivalency study of two dosage forms of test indomethacin product (25 mg capsules & 100 mg suppositories) and the treatment monitoring on patients using it", Haidar F. Hadi and Sabah Akrawi, 1999.
  8. "A two-way crossover bioavailability - bioequivalence study for formulations containing cephalixin". Qais N. Khammas and Sabah Akrawi, Thesis, 1998.
  9. "Drug registration system". Hana Y. Kinno and Sabah Akrawi, Thesis 1998.
  10. "Therapeutic drug monitoring for a test product containing 100mg atenolol and its bioavailability", Fadia Yaqub and Sabah Akrawi, Thesis, 1998.
  11. "Comparative study of three different manufacturers of atenolol tablets in hypertensive patients", Saleh A. Al-Rawi and Sabah Akrawi, Thesis 1997.
  12. "Possible drug interaction between carbamazepine and tea components in human". Muna J. Hadi and Sabah Akrawi, Thesis 1996.
  13. "Prescribing errors in selected Hospital and Private Clinics in Baghdad". Niazy Burhanaddin and Sabah H. Akrawi. 1996.
  14. "Characterization of diurnal variation during chronic intravenous infusion of carbamazepine in rats". Sufyan A. Abdullah and Sabah Akrawi, Thesis 1995.
-

- 
15. "Prescribing errors in hospitals and private clinics in Kurkuk city", Neyazy Burhanaddin and Sabah Akrawi, Thesis 1994.
  16. "Determination of renal stone's type affected by Prosopis Farcta leaves extract", Asma O. Al-Naje and Sabah Akrawi, Thesis 1994.
  17. "Nosocomial infections in three of Erbil's Hospitals". Kawa F. Dizayee and Sabah Akrawi, Thesis 1993.
- 

**Memberships**

Member of the Scientific council KFU, 2014-2018

Member of the University Promotion Committee of the Scientific Council 2017-now

Member of the University Conferences and workshops of KFU 2018-now

Member of the Translation, Authority, and Publication Center 2015-now

Chair of the postgraduate and scientific research committee 2018-now

Recruitment Committee Coordinator 2014-now

Member of the Accreditation committee

A member of the Iraqi Scientific Pharmaceutical Association.

Rho Chi, Pharmaceutical Honor Society

---

**Professional services**

1. Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.
  2. A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.
  3. A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.
  4. Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.
  5. Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.
  6. Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.
  7. Bioavailability – Bioequivalency study of formulations containing 100 mg Indomethacin as suppository , 1999.
  8. Bioavailability – Bioequivalency study of formulations containing 25 indomethacin as capsule, 1999.
  9. Bioavailability – Bioequivalency study of formulations containing 25 mg Clomipramine as tablet, 1999.
  10. Bioavailability – Bioequivalency study of formulations containing 250 mg Amoxicillin as suspension, 1999.
  11. Bioavailability – Bioequivalency study of formulations containing 250 mg methyl dopa as tablet, 1999.
  12. Bioavailability – Bioequivalency study of formulations containing 500 mg ampicillin, capsules 1999.
  13. Bioavailability – Bioequivalency study of formulations containing 150 mg clindamycin, capsules 1999.
  14. A bioequivalence study for two formulations containing carbidopa/levodopa tablets ; 2000.
  15. A bioequivalence study for two formulations containing gliclazide 80 mg tablets ; 2000.
  16. A bioequivalence study for two formulations containing clindamycin 150 mg capsules; [Clindox® vs. Dalacin C®]; 2001.
-

- 
17. A bioequivalence study for two formulations containing rifampicin 150 mg capsules; 2001.
  18. A bioequivalence study for two formulations containing rifampicin 300 mg capsules ; 2001.
  19. A bioequivalence study for two formulations containing ibuprofen 100 mg suspension ; 2001.

---

**Workshops / Seminars attended**

- (Presentation) Potentiation of gentamicin induced nephrotoxicity by molsidomine in  
4<sup>th</sup> International Pharma & Clinical Pharmacy Congress, 2016
  - (Presentation) The Evaluation of Renoprotective Effect of L-Carnitine Against Gentamicin Nephrotoxicity, 2<sup>nd</sup> International Summit on Clinical Pharmacy, 2014
  - (Presentation) Pharmacokinetic interaction between dietary black tea and carbamazepine in epileptic patients, International Summit on Clinical Pharmacy & Dispensing, 2013
-